Advertisement
U.S. markets closed

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed Price. Currency in USD
156.76-1.42 (-0.90%)
At close: 04:00PM EDT
156.76 0.00 (0.00%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close158.18
Open158.57
Bid156.78 x 800
Ask156.75 x 1000
Day's Range156.50 - 158.69
52 Week Range144.95 - 175.97
Volume6,542,717
Avg. Volume6,907,121
Market Cap377.757B
Beta (5Y Monthly)0.53
PE Ratio (TTM)30.15
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield4.76 (3.04%)
Ex-Dividend DateFeb 16, 2024
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
14% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for JNJ

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Johnson & Johnson
    Weekly Stock ListWe see what we believe are some great opportunities right now in Healthcare -- and we like the sector overall. Argus Director of Research Jim Kelleher, CFA, recently completed his quarterly sector review and raised Healthcare sector to Over-Weight from Market-Weight. The healthcare environment is undergoing rapid transitions, and we now see an unfolding period of significant promise and opportunity. Our newly-favored stance is based on resumption of deferred medical procedures and significant new quality-of-life drugs and treatments. The category is broad and has underperformed the S&P 500 over the past year. The Healthcare sector ETF (XLV) is up 15% over the past year compared to a gain of 31% for the S&P 500. We see opportunity here to pick up some steady companies, with big brands and solid financials. These companies are science-focused and enhance lives. They are innovators. In our list this week, we look across several subsectors within the Healthcare sector and pull out some leaders we like. These stocks also are included in our Focus List and Model Portfolios, as noted below.
    Rating
    Fair Value
    Economic Moat
    16 hours agoArgus Research
View more
  • GlobeNewswire

    Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

    ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leadership Team at Johnson & JohnsonSOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge. Thi

  • Business Wire

    Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

    NEW BRUNSWICK, N.J., March 11, 2024--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executi

  • Business Wire

    Johnson & Johnson Completes Acquisition of Ambrx

    NEW BRUNSWICK, N.J., March 07, 2024--Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired, as announced on January 8, 2024. The